Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Gen Hosp Psychiatry. 2009 Jun 9;31(6):531–537. doi: 10.1016/j.genhosppsych.2009.05.006

Table 2. Comparison to Prescribing Approach Taken With HCV Mono-infected Patients.

Survey Question: Does your approach to the management of depressive side effects of pegylated interferon/ribavirin treatment in HIV/HCV-co-infected patients differ from your approach in HCV mono-infected patients?

All (n=82) Non-psychiatrists* (n=58) Psychiatrists* (n=24)
Does not differ 57.3% 51.7% 70.8%
More likely to use antidepressants prior to starting treatment in HIV-co-infected 9.8% 13.8% 0%
Differs in another way 2.4% 0% 8.3%
Never treated HCV mono-infected 23.2% 29.3% 8.3%
Missing 7.3% 5.2% 12.5%
*

Prescribing Practice Differs Between Non-Psychiatrists and Psychiatrists (p<0.05)